Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28109270 | 0.82 | SREBF2 (0.39) | KDM4EALDH1A1HTR2CSLC6A4ABCG2 | |
| SCHEMBL15409505 | 0.81 | KDM4E (0.41) | KDM4EALDH1A1HTR2CSLC6A4 | |
| SCHEMBL17123710 | 0.79 | UHRF1 (0.41) | KDM4EALDH1A1HTR2CSLC6A4 | |
| SCHEMBL27592196 | 0.79 | KDM4E (0.42) | KDM4EALDH1A1 | |
| SCHEMBL15284970 | 0.79 | ALDH1A1 (0.39) | KDM4EALDH1A1HTR2CSLC6A4 | |
| SCHEMBL17832058 | 0.77 | NOS3 (0.46) | KDM4EALDH1A1HTR2CSLC6A4 | |
| SCHEMBL14948663 | 0.75 | KDM4E (0.37) | KDM4EALDH1A1HTR2CSLC6A4 | |
| SCHEMBL15285044 | 0.75 | NOS2 (0.53) | KDM4EALDH1A1 | |
| SCHEMBL21711927 | 0.73 | KDM4C (0.46) | KDM4EALDH1A1 | |
| SCHEMBL14945524 | 0.73 | KDM4E (0.35) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928210-B2 | Nucleoside based proliferation imaging markers | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20090016958-A1 | Nucleoside based proliferation imaging markers | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2009-01-15 | — | — | US | disclosed |
| WO-2008109080-A2 | NUCLEOSIDE BASED PROLIFERATION IMAGING MARKERS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109080-A2 | NUCLEOSIDE BASED PROLIFERATION IMAGING MARKERS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090016958-A1 | Nucleoside based proliferation imaging markers | MKI67, SLC29A1, SLC29A2 | KDM4E 4684/4885ALDH1A1 2624/4885HTR2C 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.